Related references
Note: Only part of the references are listed.Risk and prognostic factors of breast cancer with liver metastases
Lei Ji et al.
BMC CANCER (2021)
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
Hidetoshi Kawaguchi et al.
BREAST CANCER (2020)
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real -life ESME metastatic breast cancer cohort
Sophie Frank et al.
BREAST (2020)
Outcomes of metastatic breast cancer patients in relationship to disease-free interval following primary treatment of localized disease; a pooled analysis of two clinical trials
Omar Abdel-Rahman
BREAST JOURNAL (2019)
Overall Mortality After Diagnosis of Breast Cancer in Men vs Women
Fei Wang et al.
JAMA ONCOLOGY (2019)
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer
Ru Wang et al.
BMC CANCER (2019)
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Elisa Gobbini et al.
EUROPEAN JOURNAL OF CANCER (2018)
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
Shinichiro Kashiwagi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women
Hitoshi Inari et al.
BREAST CANCER (2017)
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
Akiko Ogiya et al.
BREAST CANCER (2017)
Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
Kenji Gonda et al.
ONCOLOGY LETTERS (2017)
Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study
Qi Wu et al.
ONCOTARGET (2017)
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
H. Kawaguchi et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions
Hitoshi Inari et al.
BMC CANCER (2017)
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer
Kokoro Kobayashi et al.
SURGERY TODAY (2016)
Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?
J. Watanabe et al.
ANNALS OF ONCOLOGY (2016)
Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer
Sho Shiino et al.
CLINICAL BREAST CANCER (2016)
Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer
Yukako Shiomi-Mouri et al.
BREAST CANCER (2016)
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence
Yuichiro Miyoshi et al.
BREAST CANCER RESEARCH (2016)
Treatment and Prognosis of Breast Cancer Patients with Brain Metastases According to Intrinsic Subtype
Sayaka Kuba et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Factors responsible for long-term survival in metastatic breast cancer
Keiichi Kontani et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Pretreatment serum levels of myeloid-derived suppressor cells (MSC) are effective as a prognostic indicator in patients with breast cancer.
Kenji Gonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Assessing Bias in Studies of Prognostic Factors
Jill A. Hayden et al.
ANNALS OF INTERNAL MEDICINE (2013)
PROGNOSTIC FACTORS PREDICTING SURVIVAL AFTER FIRST RECURRENCE IN PATIENTS WITH METASTATIC BREAST CANCER
Masahiro Hikichi et al.
BREAST (2013)
Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer
Akiko Kawano et al.
BREAST CANCER (2013)
Prognostic factors and survival in metastatic breast cancer: A single institution experience
Afef Khanfir et al.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2013)
Immunohistochemical Detection of Breast Cancer Stem Cells in Hormone Receptor-Positive Breast Cancer and Their Role in Response to Endocrine Therapy and Clinical Outcome
Kenji Hashimoto et al.
ONCOLOGY (2012)
KI-67 EXPRESSION PREDICTS CLINICAL OUTCOME IN LOCALLY ADVANCED BREAST CANCER
Naomi Kobayashi et al.
BREAST (2011)
Expression of Estrogen Receptor Beta and Phosphorylation of Estrogen Receptor Alpha Serine 167 Correlate with Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Aromatase Inhibitors
Kazuyoshi Motomura et al.
ONCOLOGY (2010)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Prognostic factors in 1038 women with metastatic breast cancer
R. Largillier et al.
ANNALS OF ONCOLOGY (2008)
Share Paper
